UMIN-ICDS Clinical Trial

Public title

Effects of test food consumption on liver function in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Acronym

Effects of test food consumption on liver function in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title

Effects of test food consumption on liver function in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

Effects of test food consumption on liver function in healthy Japanese

Region

Japan

Condition

Healthy Japanese

Classification by specialty

Not applicable

Adult

Classification by malignancy

Others

Genomic information

NO

Narrative objectives1

To verify the effects of test food consumption on liver function in healthy Japanese.

Basic objectives2

Efficacy

Basic objectives -Others

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable

Primary outcomes

1. Measured value of ALT (GPT) at 4 weeks after the intervention (4w)

Key secondary outcomes

1. Change and percentage change in ALT (GPT) from screening to 4w

2. Measured values of AST (GOT) and gamma-GT (gamma-GTP) at 4w, and their changes and percentage changes from screening

3. Measured values for physical weariness, facial swelling, leg swelling, and body swelling at 4w, and their change and percentage change from screening

4. Individuals who experienced adverse events

5 Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at screening

6. Physical measurements, urinalysis, and peripheral blood test

Study type

Interventional

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

Dynamic allocation

Institution consideration

Institution is not considered as adjustment factor.

Blocking

Concealment

Central registration

No. of arms

4

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Food

Interventions/Control_1

Duration: 4 weeks
Test product: Kange Suibonsou 9 tablets (0 placebo tablets)
Administration: Consume 9 tablets of Kange Suibonsou per day with water

*If a dose is missed, it should be consumed as soon as remembered. The daily dose should be consumed within the same day and should not be carried over to the following day.

Interventions/Control_2

Duration: 4 weeks
Test product: Kange Suibonsou 6 tablets (3 placebo tablets)
Administration: Consume a total of 9 tablets per day (6 tablets of Kange Suibonsou and 3 placebo tablets) with water

*If a dose is missed, it should be consumed as soon as remembered. The daily dose should be consumed within the same day and should not be carried over to the following day.

Interventions/Control_3

Duration: 4 weeks
Test product: Kange Suibonsou 4 tablets (5 placebo tablets)
Administration: Consume a total of 9 tablets per day (4 tablets of Kange Suibonsou and 5 placebo tablets) with water

*If a dose is missed, it should be consumed as soon as remembered. The daily dose should be consumed within the same day and should not be carried over to the following day.

Interventions/Control_4

Duration: 4 weeks
Test product: Kange Suibonsou 0 tablets (9 placebo tablets)
Administration: Consume 9 placebo tablets per day with water

*If a dose is missed, it should be consumed as soon as remembered. The daily dose should be consumed within the same day and should not be carried over to the following day.

Interventions/Control_5

Interventions/Control_6

Interventions/Control_7

Interventions/Control_8

Interventions/Control_9

Interventions/Control_10

Age-lower limit

18

years-old

<=

Age-upper limit

Not applicable

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Adults

4. Healthy individuals

5. Individuals whose ALT (GPT) level is >=30 U/L at screening

Key exclusion criteria

1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction

2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator

3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims

5. Individuals who are taking or using medications (including herbal medicines) or supplements

6. Individuals who are allergic to medications or foods related to the test product

7. Individuals who are pregnant, lactating, or planning pregnancy during this study

8. Individuals who are deemed unsuitable for participation in this study by the principal investigator

Target sample size

80

Name of lead principal investigator

1st name	Tsuyoshi
Middle name
Last name	Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com

Name of contact person

1st name	Naoko
Middle name
Last name	Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL

Email

nao@orthomedico.jp

Institute

MAINICHIEGAO. CO., LTD.

Institute

Department

Personal name

Organization

MAINICHIEGAO. CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Co-sponsor

Name of secondary funder(s)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com

Secondary IDs

NO

Study ID_1

Org. issuing International ID_1

Study ID_2

Org. issuing International ID_2

IND to MHLW

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)

Date of disclosure of the study information

2026

Year

07

Month

01

Day

URL releasing protocol

Publication of results

Unpublished

URL related to results and publications

Number of participants that the trial has enrolled

Results

Results date posted

Results Delayed

Results Delay Reason

Date of the first journal publication of results

Baseline Characteristics

Participant flow

Adverse events

Outcome measures

Plan to share IPD

IPD sharing Plan description

Recruitment status

Open public recruiting

Date of protocol fixation

2026

Year

06

Month

10

Day

Date of IRB

2026

Year

06

Month

10

Day

Anticipated trial start date

2026

Year

07

Month

01

Day

Last follow-up date

2026

Year

11

Month

20

Day

Date of closure to data entry

Date trial data considered complete

Date analysis concluded

Other related information

<Statistical analysis details>
Subgroups will be defined based on the factors in the following variables.

AST (GOT): <=30 / 31-35 / 36-50 / >=51
ALT (GPT): 31-40 / 41-50 / >=51 / <=50
gamma-GT (gamma-GTP): <=50 / 51-80 / 81-100 / >=101
Age: >=40 / <40 / >=65 / <65
Sex: Male / Female
BMI (kg/m²): <18.5 / >=18.5 and <25.0 / >=25.0

Registered date

2026

Year

07

Month

01

Day

Last modified on

2026

Year

07

Month

01

Day

Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000071062